1. Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study
- Author
-
Wan Seop Kim, Jong Sik Lee, In Ae Kim, Hee Joung Kim, and Kye Young Lee
- Subjects
0301 basic medicine ,Oncology ,Male ,Lung adenocarcinoma ,Cancer Research ,medicine.medical_specialty ,Lung Neoplasms ,Afatinib ,Adenocarcinoma of Lung ,EGFR-TKIs ,lcsh:RC254-282 ,03 medical and health sciences ,0302 clinical medicine ,Gefitinib ,Internal medicine ,Genetics ,Medicine ,Humans ,Osimertinib ,Protein Kinase Inhibitors ,Retrospective Studies ,Performance status ,business.industry ,Hazard ratio ,Smoking ,Middle Aged ,medicine.disease ,Prognosis ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,EGFR mutations ,Progression-Free Survival ,respiratory tract diseases ,ErbB Receptors ,030104 developmental biology ,030220 oncology & carcinogenesis ,Recurrent Lung Adenocarcinoma ,Mutation ,Adenocarcinoma ,Female ,Cumulative smoking dose ,Erlotinib ,business ,medicine.drug ,Research Article - Abstract
Background Although lung adenocarcinoma with activating epidermal growth factor receptor (EGFR) mutations is common in never smokers, one-third of the patients are ever-smokers. We aimed to investigate the effect of cumulative smoking dose(CSD) on clinical outcomes, including progression-free survival (PFS) and overall survival (OS), in patients with EGFR-mutated lung adenocarcinoma receiving EGFR-tyrosine kinase inhibitors (TKIs). Methods We retrospectively analyzed 142 patients with EGFR-mutation positive advanced or recurrent lung adenocarcinoma who were administered gefitinib, erlotinib, afatinib, and osimertinib. These patients were classified based on their CSD as never smokers, light smokers (≤10 pack-years [PYs]), moderate smokers (11–30 PYs), and heavy smokers (> 30 PYs). PFS and OS were analyzed according to smoking subgroups via Kaplan-Meier curves. Results Among the 142 patients, 91 (64.1%), 12 (8.5%), 22 (15.5%), and 17 (12%) were never, light, moderate, and heavy smokers, respectively. CSD was inversely associated with median PFS in a statistically significant dose-dependent manner (11.8 months (mo), 11.0 mo, 7.4 mo, and 3.9 mo; p
- Published
- 2018
- Full Text
- View/download PDF